Who Does Collegium Pharmaceutical Company Compete With?

In pain management, key direct rivals are Purdue Pharma (OxyContin) and generic opioid manufacturers including Teva and Endo International. In ADHD, post – Ironshore acquisition, Collegium now competes with Takeda and major generic stimulant producers for market share and formulary slots.

Non – opioid entrants and device/behavioral pain treatments are indirect threats; Vertex's Journavx approval in January 2025 is a systemic substitute for opioid therapy. Payers and hospitals favor lower – cost generics and non – opioid protocols, squeezing demand for abuse – deterrent opioids.

The battle is mainly about price and formulary placement, plus technology (abuse – deterrent formulation). Brand and payer contracts matter; product differentiation (abuse deterrence) helps, but lower – cost generics win on price and volume.

Purdue Pharma remains the most important incumbent in branded ER opioids for prescribing habits, while Vertex's Journavx is the single biggest strategic threat after its Jan 2025 FDA approval because it reduces systemic reliance on opioids.

Strongest pressure comes from generic extended – release oxycodone makers compressing prices, payer formulary exclusions favoring generics/non – opioids, and new non – opioid approvals shifting treatment guidelines and hospital procurement.

Market access determines revenue: Collegium reported net product sales in fiscal 2025 that hinge on formulary placement of abuse – deterrent Xtampza ER and ADHD assets; displacement by generics or Journavx would materially reduce addressable market and long – term growth.

DETERx gives Xtampza ER a Category 2 abuse – deterrent formulation (ADF) designation, resisting crushing and chemical tampering while preserving extended release. That technical moat differentiates Collegium Pharmaceutical versus many pharmaceutical competitors in pain management and abuse – deterrent opioid competitors.

Payers favor ADFs for risk management and liability reduction, so Xtampza ER secures preferred formulary placement more easily than non – ADF generics. Patients and prescribers value maintained efficacy with lower manipulation risk, keeping loyalty amid Collegium Pharmaceutical rival companies.

DETERx is a platform, not a single product, allowing product extensions and pipeline leverage versus generic opioid manufacturers competing with Collegium. Jornay PM (ADHD) added a new revenue axis, driving net revenue for that franchise to 148.9 million USD in FY 2025, up 48% year – over – year.

Commercial execution on Xtampza ER and Jornay PM expanded market access and channel penetration, and the company ended FY 2025 with 386.7 million USD in cash and marketable securities, enabling defensive pricing, rebates, and accretive M&A to counter companies competing with Collegium Pharmaceutical.

Dependence on a small number of branded products exposes Collegium to patent cliffs, generic opioid manufacturers competing with Collegium, and competitive ADF entrants; payers may still prefer lower – cost alternatives for broad pain portfolios, pressuring margins versus larger Collegium Pharmaceutical market competitors in pain management industry.

The combination of a validated Category 2 ADF platform, accelerating non – opioid/adjacent revenue from Jornay PM, and 386.7 million USD liquidity at FY 2025 creates a defendable position versus Collegium Pharmaceutical competitors, allowing sustained formulary negotiation power and selective M&A to shore up weaknesses. See ecosystem context in Who Collegium Pharmaceutical Company Serves